NCT01121562View on ClinicalTrials.gov

Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

November 30, 2013

Conditions
Pancreatic Neuroendocrine Tumors
Interventions
DRUG

Sunitinib

Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)

Trial Locations (4)

Unknown

Aichi Cancer Center Central Hospital, Nagoya

Kyushu University Hospital, Fukuoka

Osaka Police Hospital, Osaka

National Cancer Center Hospital, Chuo-ku

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY